Cempra Holdings (CEMP) Misses Q2 EPS by 3c

Cempra Holdings (NASDAQ: CEMP) reported Q2 EPS of ($0.51), $0.03 worse than the analyst estimate of ($0.48).

Financial Guidance

Cempra expects its research and development expense to continue at least at current levels for the next several quarters due to the concurrent running of its two phase 3 programs for solithromycin as well as its other programs. The company's cash and equivalents are expected to be sufficient to fund current operations through 2015, based on current assumptions. This projection does not include any funds from future financings or partnerships beyond the Toyama and BARDA relationships.

For earnings history and earnings-related data on Cempra Holdings (CEMP) click here.

You May Also Be Interested In

• Burry doubles down on Nebius short after stock surges 34% on earnings
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
• Parker Hannifin completes acquisition of Filtration Group Corporation